Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Activation of Oncogenic Super-Enhancers Is Coupled with DNA Repair by RAD51.

Hazan I, Monin J, Bouwman BAM, Crosetto N, Aqeilan RI.

Cell Rep. 2019 Oct 15;29(3):560-572.e4. doi: 10.1016/j.celrep.2019.09.001.

2.

AntimiR-155 Cyclic Peptide-PNA Conjugate: Synthesis, Cellular Uptake, and Biological Activity.

Soudah T, Khawaled S, Aqeilan RI, Yavin E.

ACS Omega. 2019 Aug 12;4(9):13954-13961. doi: 10.1021/acsomega.9b01697. eCollection 2019 Aug 27.

3.

Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders.

Chang NS, Lin R, Sze CI, Aqeilan RI.

Front Oncol. 2019 Aug 2;9:719. doi: 10.3389/fonc.2019.00719. eCollection 2019. No abstract available.

4.

Correction: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation.

Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

J Biol Chem. 2019 Jun 21;294(25):10018. doi: 10.1074/jbc.AAC119.009552. No abstract available.

5.

Correction: Negative Regulation of the Hippo Pathway by E3 Ubiquitin Ligase ITCH Is Sufficient to Promote Tumorigenicity.

Salah Z, Melino G, Aqeilan RI.

Cancer Res. 2019 Jun 1;79(11):3007. doi: 10.1158/0008-5472.CAN-19-1086. No abstract available.

6.

Decoding the link between WWOX and p53 in aggressive breast cancer.

Abdeen SK, Aqeilan RI.

Cell Cycle. 2019 Jun;18(11):1177-1186. doi: 10.1080/15384101.2019.1616998. Epub 2019 May 16.

PMID:
31075076
7.

MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.

Maximov VV, Akkawi R, Khawaled S, Salah Z, Jaber L, Barhoum A, Or O, Galasso M, Kurek KC, Yavin E, Aqeilan RI.

Int J Cancer. 2019 Dec 1;145(11):3052-3063. doi: 10.1002/ijc.32368. Epub 2019 May 9.

PMID:
31018244
8.

Fhit-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells.

Druck T, Cheung DG, Park D, Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Raso C, Green K, Huebner K, Croce CM.

Cell Death Dis. 2019 Feb 15;10(3):147. doi: 10.1038/s41419-019-1414-7.

9.

WWOX somatic ablation in skeletal muscles alters glucose metabolism.

Abu-Remaileh M, Abu-Remaileh M, Akkawi R, Knani I, Udi S, Pacold ME, Tam J, Aqeilan RI.

Mol Metab. 2019 Apr;22:132-140. doi: 10.1016/j.molmet.2019.01.010. Epub 2019 Jan 31.

10.

WWOX Inhibits Metastasis of Triple-Negative Breast Cancer Cells via Modulation of miRNAs.

Khawaled S, Suh SS, Abdeen SK, Monin J, Distefano R, Nigita G, Croce CM, Aqeilan RI.

Cancer Res. 2019 Apr 15;79(8):1784-1798. doi: 10.1158/0008-5472.CAN-18-0614. Epub 2019 Jan 8.

PMID:
30622118
11.

Author Correction: WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia.

Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI.

Cell Death Dis. 2018 Nov 23;9(12):1159. doi: 10.1038/s41419-018-1158-9.

12.

Modeling WWOX Loss of Function in vivo: What Have We Learned?

Tanna M, Aqeilan RI.

Front Oncol. 2018 Oct 10;8:420. doi: 10.3389/fonc.2018.00420. eCollection 2018. Review.

13.

Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer.

Abdeen SK, Ben-David U, Shweiki A, Maly B, Aqeilan RI.

Cell Death Dis. 2018 Aug 6;9(8):832. doi: 10.1038/s41419-018-0896-z.

14.

Microenvironmental Cues Determine Tumor Cell Susceptibility to Neutrophil Cytotoxicity.

Gershkovitz M, Fainsod-Levi T, Khawaled S, Shaul ME, Sionov RV, Cohen-Daniel L, Aqeilan RI, Shaul YD, Fridlender ZG, Granot Z.

Cancer Res. 2018 Sep 1;78(17):5050-5059. doi: 10.1158/0008-5472.CAN-18-0540. Epub 2018 Jul 2.

15.

MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression.

Ma L, Yang X, Wei R, Ye T, Zhou JK, Wen M, Men R, Li P, Dong B, Liu L, Fu X, Xu H, Aqeilan RI, Wei YQ, Yang L, Peng Y.

Cell Death Dis. 2018 Jun 18;9(7):718. doi: 10.1038/s41419-018-0752-1.

16.

WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia.

Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI.

Cell Death Dis. 2018 May 1;9(5):511. doi: 10.1038/s41419-018-0510-4. Erratum in: Cell Death Dis. 2018 Nov 23;9(12):1159.

17.

TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells.

Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, Lev S, Polyansky L, Shaul ME, Sionov RV, Cohen-Daniel L, Aqeilan RI, Shaul YD, Mori Y, Karni R, Fridlender ZG, Binshtok AM, Granot Z.

Cancer Res. 2018 May 15;78(10):2680-2690. doi: 10.1158/0008-5472.CAN-17-3614. Epub 2018 Feb 28.

18.

TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.

Gaudio E, Paduano F, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan RI, Croce CM, Bertoni F, Alcaro S, Trapasso F.

Br J Haematol. 2018 Nov;183(3):509-512. doi: 10.1111/bjh.14989. Epub 2017 Oct 19. No abstract available.

PMID:
29048125
19.

Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells.

Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM.

J Biol Chem. 2017 Aug 25;292(34):14279. doi: 10.1074/jbc.A117.709062. No abstract available.

20.

RUNX1, a new regulator of EMT in breast cancer.

Khawaled S, Aqeilan RI.

Oncotarget. 2017 Mar 14;8(11):17407-17408. doi: 10.18632/oncotarget.15623. No abstract available.

Supplemental Content

Loading ...
Support Center